Multiple Sclerosis – Roche CN46182
Multiple Sclerosis Research Study
Information Regarding an Investigational Device Research Study for Adults with Multiple Sclerosis
Profound Research and The Neurology Center of Southern California are enrolling adults with Multiple Sclerosis (MS) in an investigational device study to assess whether they or their caregivers can successfully use the investigational device to administer ocrelizumab approximately every six months for three doses. Participation is optional, see preliminary information below.
To be eligible to participate, you must:
- Be 18-65 years of age
- Have a diagnosis of Multiple Sclerosis
- Currently be treated with ocrelizumab (Ocrevus)
- Be willing to receive injections using the investigational device, either self-administered or by a caregiver
Additional criteria apply.
Qualified participants will receive:
- Study-related care and investigational medication at no cost
- Financial compensation for time and travel may be available
Call us at 619-489-5613 or complete the form and our team will reach out soon to help determine your eligibility.
We take your privacy and preferences seriously. For information on our data practices, you can review our privacy policy. If you no longer wish to receive emails regarding this clinical research study, please contact us at patientinfo@profoundresearch.com.
